GlassScriptPhysician profile
Angelo M Barile
NPI 1558370148
$4,668.64
in general payments reported to CMS, 2019-2025
31 companies · $595 in 2025
The $595 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,423 · 2020: $549 · 2021: $667 · 2022: $468 · 2023: $480 · 2024: $488 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $522.72 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $483.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $458.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $447.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.99 | 2019-2025 | Spiriva Respimat, Tradjenta, Jardiance |
| Merck Sharp & Dohme LLC | $221.77 | 2019-2025 | Gardasil 9, Verquvo, Dificid |
| Smith+Nephew, INC. | $210.55 | 2019-2023 | Collagenase Santyl |
| Novartis Pharmaceuticals Corporation | $201.48 | 2019-2024 | |
| Pfizer INC. | $190.73 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $183.48 | 2019-2023 | Xarelto |
| Abbvie INC. | $168.11 | 2019-2025 | Vraylar, Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $156.58 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $146.85 | 2019-2023 | Prolia, Evenity |
| Biohaven Pharmaceuticals, INC. | $146.36 | 2021 | |
| Abbott Laboratories | $121.31 | 2022-2024 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $93.11 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $87.53 | 2019-2021 | |
| Allergan, INC. | $80.72 | 2019-2020 | |
| Exact Sciences Corporation | $78.49 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Avanir Pharmaceuticals, INC. | $69.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $65.47 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.92 | 2023-2024 | Xifaxan |
| Dexcom, INC. | $44.41 | 2021-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $38.11 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.36 | 2022 | |
| Evoke Pharma, INC. | $32.92 | 2023-2025 | Gimoti |
| Viatris Specialty LLC | $19.76 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $18.34 | 2025 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $13.78 | 2023 | Krystexxa |
| Melinta Therapeutics, LLC | $11.25 | 2019 | |
| Aroa Biosurgery Incorporated | $9.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Barile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.